Testimony: Reforming the 340B Drug Pricing Program and Ensuring Access to Affordable Medications

Feldman expresses support for reforming the 340B program—which has grown to over $65 billion in annual drug purchases—through improved transparency, stronger HRSA oversight, limits on child sites and contract pharmacies, clearer community benefit standards, and other measures. However, he emphasizes that 340B reform alone will not lower US drug prices and should be paired with other reforms, including protecting and expanding Medicare drug price negotiation, combating patent thickets, and preserving Medicaid and ACA coverage for vulnerable patients. Watch his testimony.